Member Info for DaddyAIM

In Asia, we see positive developments. Malaysia, Indonesia and Philippines all appear to have re-entered the infection control stage post-resurgence. This should lead to positive implications for their respective equity markets. More broadly, we think the evidently declining mortality rates argue for public health priority shifting toward patient treatment from interrupting infection spread

Daily new additions jumped in Malaysia in the past week, adding daily cases in the range of 589-865 (vs. an average of 735/487 cases in past week/two weeks ago). That said, cumulative cases in Malaysia reached ~21k, with ~12k cases in the second wave of infection so far. However, the transmission rate in the country was unchanged at around 1.3x after broadly following a falling trend. Almost all of the cases are local cases, and most come from Sabah district (~61% of new cases over the past week), followed by Kedah/Selangor district (22%/7% of new cases over the past week). The state of Sabah/Selangor went under partial lockdown starting 11 October, closing shopping malls, offices and mosques for one to two weeks.

We forecasts that the second wave of infection could add ~15k cumulative infections in the country by the end of November. We expect the curve to peak by mid-October (vs. our previous estimate of early October). Hence, in total, we think Malaysia could reach ~24k cumulative infections by the end of November.

"Frontier IP, an IP commercialisation company, has showed a strong FY’20 (period-end 30 June 2020) financial performance, in line with our cash flow expectations set out in our September note but make no changes at this juncture. Notably, net income from the unrealised revaluation of investments was up 55% to £6.0m, slightly ahead of our expectations of £5.8m. NAV/share grew 23% to 51.0p vs. 41.4p 30 June 2019, enjoying a 5 year CAGR of 19%. Results cap a fine period of news flow and portfolio progress has continued into FY’21 despite the ongoing COVID-19 pandemic, and we believe a number of companies are now at important inflection points in their development. Whilst COVID-19 has impacted portfolio companies differently, overall the portfolio continues to remain a net benefiter, chiefly driven by direct opportunities at The Vaccine Group, Elute Intelligence and Exscientia. The July fundraise of £2.2m (net) has significantly strengthened the balance sheet and management are well placed to execute its strategy to support portfolio progress and deploy additional capital via bridge financing if required."

Q1 revs 44% ahead yoy, with revenue visibility against current market forecasts for the year ending 30 June 2021 now at 88%. £5.0m cash, net cash after debt £2.7m

1H Revs+14%, FCF+11%, EBITDA and PBT +25%, "Gross margin is beginning to trend ahead of HY20 and is 2pts higher than the diluted FY20 full year margin"

Sorry all, not looking for a lengthy explanation but why is the SP being beaten?
the firm looks well positioned for growth in regards to future policies.
also nothing odd in RNS.
many thanks !

I wonder why this stock is so unloved.
Ok management is not the best but the business itself is going very well.
lockdown / covid or not, REACT will perform.

Don't forget, LSE has no idea if the order is a BUY or a SELL.
The platform guesstimates by comparing the execution price to the current mid.
If the execution price is > mid = BUY
If the execution price is < mid = SELL

well guys... with such a large spread loads is going on above and below mid!!!!!!

Best way to back that is to look at today's share price, +1.8% at time of writing but if you look at the trade board, it's filled with red. Well loads of these "red" are actually buys!

Malaysia on Tuesday announced the reintroduction of movement restriction measures in several areas including the capital city of Kuala Lumpur in a bid to contain the recent spike of coronavirus. I believe this is the cause of such a negative price momentum.

However looking at RNS from 15/june ie. when Malaysia was under strict lock down.

"COVID-19 has not negatively affected the financial performance of the Group and the Directors remain confident on the prospects for the Group for the remainder of 2020 particularly in the mobile phone prepaid airtime reload and bill payment business in Malaysia"
"Given the nature of the Group's major business in e-payment, the Group's financial performance in Malaysia has not been adversely affected by COVID-19."

In fact, the RNS from the 30/09 confirmed it once again:

"Given the nature of the Group's major business in e-payments, the Group's financial performance in Malaysia has not been adversely affected by COVID-19 as more mobile phone users are purchasing the prepaid airtime reload via mobile banking, internet banking and e-wallets applications."

=> stay strong, the current momentum is resulting from weak hands investors. MBO remains a strong buy on any metrics, fundamentals and qualitatives.

ok pal - rarely read so much BS-t.

you warned about what?
"Back to this stock , at time’s its just too good to be true , maybe it is. Just be careful and invest what you can afford to.
Numbers are massive ..... sp is very small ..... you work it out .... if the numbers in revenue ever dropped its lights out here."

where in these sentences you give some concrete arguments? just narrative upon share price momentum. bug.
Also you've never said you were short.
Assuming you were, you short a share with a 15% spread? liar. GTFO bug.

Summary: PT: 1,365p (base scenario) - 3000p (bull case) !!!!

"A new diagnostics leader emerges

With COVID-19 driving exponential demand for diagnostics and PCR the testing gold standard, PCR specialist Novacyt had strong competitive advantages in place to benefit, but the company's execution is where it has truly distinguished itself in 2020. It responded quickly to capture first mover advantage and has delivered multiple C-19 products to market at scale, driving an inflection in its revenues and significant growing cash flow. The rise in strategic importance of diagnostics is set to continue, and Novacyt has set out a credible, deliverable strategy to emerge as a long-term winner. We initiate with a Buy recommendation and initial 1,365p scenario-based target, with our blue-sky scenario of a sustained step-up in revenues into the long term seeing value north of £30. Buy"

China threatens to create REE black list for foreign companies

• China is looking to punish foreign nations and companies through restrictions on the availability of REEs ‘Rare Earth Elements’
• China claims this list will be similar to the US Department of Commerce "entity list" for foreign companies that trade with North Korea or Iran, or are accused of illegal acts such as money laundering or forced labour, etc (ATF)
• China passed draft legislation three years ago, reviewing the legislation twice since.
• The National People's Congress is also expected to review this ‘draft’ legislation again next week ahead of its potential decree and implementation next year.
• The legislation is a major and serious threat to Western manufacturers though China has been carefully restricting the availability of key REEs for some time using export quotas and generally preferring companies with manufacturing bases located in China.

=> TIME TO SWITCH TO AFRICA => LONG RBW !

China threatens to create REE black list for foreign companies

• China is looking to punish foreign nations and companies through restrictions on the availability of REEs ‘Rare Earth Elements’
• China claims this list will be similar to the US Department of Commerce "entity list" for foreign companies that trade with North Korea or Iran, or are accused of illegal acts such as money laundering or forced labour, etc (ATF)
• China passed draft legislation three years ago, reviewing the legislation twice since.
• The National People's Congress is also expected to review this ‘draft’ legislation again next week ahead of its potential decree and implementation next year.
• The legislation is a major and serious threat to Western manufacturers though China has been carefully restricting the availability of key REEs for some time using export quotas and generally preferring companies with manufacturing bases located in China.

=> TIME TO SWITCH TO AFRICA => LONG RBW !

up

missing the cheeky 7m...
adjusting... c. 5% downside.

Nbr New Share @175p = 49,714,286
Total Nbr share post Issuance= 199,147,728
Issue price= 175p
Close price before RNS out = 226p

Implied share price= 213.3

may the force be with y'all

Implied share price post issuance 214.1p, c. -5% downside

inputs:

Nbr New ordinary Share @175p = 45,714,286
Total Nbr share post Issuance= 195,147,728
Issue price= 175
Close price before RNS = 226

Can any AGM holder explain the advantage of AGM over DCTA ? thanks
DCTA looks much more "premium" at every level.

Clearly under UNWARRANTED selling pressure.
If any sellers is hanging around this post, please share your thoughts and arguments.
Cheers!

Remember, LSE has no clue if it's a BUY or a SELL.
They take the mid price, if the execution price is above (the mid) it's a buy, if it's below, it's a sell.
My BUY just got filled below mid and shows at a SELL on the LSE "share trades"...

we might see a need form the UK government to diversify its supply source. Initiated a long here...